trial

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

NCTId NCT03892889
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 277 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2020-08-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
277 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-04-29
Primary completion
2020-08-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

68 total
Phoenix, United StatesLittle Rock, United StatesAnaheim, United StatesBellflower, United StatesCerritos, United StatesColton, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesGranada Hills, United StatesLancaster, United StatesLemon Grove, United States

Linked catalysts

1
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-mon — primary completion2020-08-12

Facts & assertions

4 sourced
Enrollment
277
Phase
PHASE3
Primary Completion Date
2020-08-12
Status
TERMINATED
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication